Innogen Pharma jostles for a slice of the weight-loss market
The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
PegBio aims to bulk up its finances to deliver weight-loss drugs
The Chinese developer of anti-obesity and diabetes drugs has applied for a Hong Kong listing to fund its commercial plans, but will face strong competition Key Takeaways: The company’s core…
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on…
AI drugs researcher QuantumPharm makes market debut on long road to profit
The newly floated biotech can boast big-name backers and counts more than a dozen biopharma heavyweights among its customers, but it is still awash with red ink Key Takeaways: QuantumPharm’s…
ProfoundBio discovers the joys of having a wealthy owner
The company has become the latest in a recent string of China-related innovative drug makers to be purchased by larger foreign buyers Key Takeaways: Cancer treatment maker ProfoundBio announced it…
Recent Articles
RELATED ARTICLES
-
PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
